Charles Schwab Investment Management Inc. Increases Holdings in iTeos Therapeutics, Inc. $ITOS

Charles Schwab Investment Management Inc. raised its stake in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 17.3% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 233,561 shares of the company's stock after acquiring an additional 34,365 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.61% of iTeos Therapeutics worth $1,394,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Jacobs Levy Equity Management Inc. lifted its holdings in shares of iTeos Therapeutics by 347.9% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 922,134 shares of the company's stock valued at $7,082,000 after purchasing an additional 716,271 shares during the last quarter. Millennium Management LLC grew its position in iTeos Therapeutics by 1,008.8% during the 4th quarter. Millennium Management LLC now owns 411,072 shares of the company's stock worth $3,157,000 after purchasing an additional 373,999 shares during the period. Dimensional Fund Advisors LP grew its position in iTeos Therapeutics by 15.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,210,080 shares of the company's stock worth $9,293,000 after purchasing an additional 163,880 shares during the period. Raymond James Financial Inc. acquired a new stake in iTeos Therapeutics during the 4th quarter worth about $1,159,000. Finally, Ameriprise Financial Inc. grew its position in shares of iTeos Therapeutics by 233.6% during the 4th quarter. Ameriprise Financial Inc. now owns 205,188 shares of the company's stock valued at $1,576,000 after acquiring an additional 143,672 shares during the period. Institutional investors own 97.16% of the company's stock.

iTeos Therapeutics Stock Performance

Shares of ITOS opened at $10.15 on Tuesday. The firm's 50-day moving average is $10.14 and its two-hundred day moving average is $8.46. iTeos Therapeutics, Inc. has a twelve month low of $4.80 and a twelve month high of $17.63. The firm has a market capitalization of $448.73 million, a P/E ratio of -2.17 and a beta of 1.31.

iTeos Therapeutics (NASDAQ:ITOS - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($1.51) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.39). Analysts predict that iTeos Therapeutics, Inc. will post -3.49 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on ITOS shares. Wells Fargo & Company decreased their price target on shares of iTeos Therapeutics from $12.00 to $11.00 and set an "equal weight" rating on the stock in a research note on Thursday, August 7th. HC Wainwright lowered shares of iTeos Therapeutics from a "buy" rating to a "neutral" rating in a research report on Wednesday, May 14th. Leerink Partnrs lowered iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, May 14th. Wedbush reissued an "outperform" rating and issued a $10.50 target price (down previously from $12.00) on shares of iTeos Therapeutics in a research report on Monday, July 21st. Finally, Raymond James Financial set a $12.00 price target on shares of iTeos Therapeutics in a research note on Wednesday, May 14th. One investment analyst has rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, iTeos Therapeutics currently has a consensus rating of "Hold" and a consensus target price of $15.50.

Get Our Latest Report on iTeos Therapeutics

Insider Activity at iTeos Therapeutics

In related news, CEO Michel Detheux sold 43,883 shares of the company's stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $10.02, for a total transaction of $439,707.66. Following the transaction, the chief executive officer owned 153,903 shares of the company's stock, valued at approximately $1,542,108.06. This represents a 22.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director David Hallal sold 38,228 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The disclosure for this sale can be found here. Insiders have sold 277,185 shares of company stock worth $2,805,412 in the last three months. Insiders own 14.20% of the company's stock.

iTeos Therapeutics Profile

iTeos Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Featured Articles

• Five stocks we like better than iTeos Therapeutics
• 3 Must-Buy Warren Buffett Stocks for Volatile Times
• 3 Healthcare Pathbreakers With Long-Term Tailwinds
• 3 Warren Buffett Stocks to Buy Now
• 3 Tariff-Proof Retailers Making New All-time Highs
• Are Penny Stocks a Good Fit for Your Portfolio?
• With Shares Near Highs, Here's to Watch in Broadcom's Q3 Report

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in iTeos Therapeutics Right Now?

Before you consider iTeos Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and iTeos Therapeutics wasn't on the list.

While iTeos Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here